PE20050130A1 - Compuestos organicos - Google Patents
Compuestos organicosInfo
- Publication number
- PE20050130A1 PE20050130A1 PE2003000791A PE2003000791A PE20050130A1 PE 20050130 A1 PE20050130 A1 PE 20050130A1 PE 2003000791 A PE2003000791 A PE 2003000791A PE 2003000791 A PE2003000791 A PE 2003000791A PE 20050130 A1 PE20050130 A1 PE 20050130A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- organic compounds
- alkylene
- compounds
- adjacents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I EN FORMA LIBRE, DE SAL O DE SOLVATO, DONDE X ES -R1-Ar-R2, -Ra-Y; Ar ES FENILENO SUSTITUIDO; R1 Y R2, UNIDOS A LOS C ADYACENTES DE Ar FORMAN UN ANILLO CICLOALIFATICO DE 5 A 7 MIEMBROS, O R1 ES ALQUILENO C1-C10 Y R2 ES H, ALQUILO C1-C10, Ra ES ENLACE O ALQUILENO C1-C10 OPCIONALMENTE SUSTITUIDO; Y ES ALQUILO C1-C10, ALCOXILO C1-C10, ALQUENILO C2-C10, ENTRE OTROS. TAMBIEN REFERIDO A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, UN PROCESO PARA LA PREPARACION DE ESTOS COMPUESTOS QUE ACTIVAN EL ADRENORECEPTOR-B2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0218629A GB0218629D0 (en) | 2002-08-09 | 2002-08-09 | Organic compounds |
GB0220955A GB0220955D0 (en) | 2002-09-10 | 2002-09-10 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050130A1 true PE20050130A1 (es) | 2005-03-29 |
Family
ID=31889675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000791A PE20050130A1 (es) | 2002-08-09 | 2003-08-07 | Compuestos organicos |
Country Status (22)
Country | Link |
---|---|
US (3) | US20060106075A1 (es) |
EP (1) | EP1529038B1 (es) |
JP (1) | JP4541145B2 (es) |
KR (1) | KR20070064687A (es) |
AR (1) | AR040962A1 (es) |
AT (1) | ATE444958T1 (es) |
AU (1) | AU2003255400B2 (es) |
BR (1) | BR0313723A (es) |
CA (1) | CA2493765C (es) |
DE (1) | DE60329601D1 (es) |
EC (1) | ECSP055582A (es) |
ES (1) | ES2331879T3 (es) |
IL (1) | IL166334A0 (es) |
MX (1) | MXPA05001613A (es) |
NO (1) | NO20051165L (es) |
NZ (1) | NZ538021A (es) |
PE (1) | PE20050130A1 (es) |
PL (1) | PL374314A1 (es) |
PT (1) | PT1529038E (es) |
RU (1) | RU2324687C2 (es) |
TW (1) | TW200408630A (es) |
WO (1) | WO2004016601A1 (es) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20050130A1 (es) * | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
ES2329586T3 (es) | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0402797D0 (en) * | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
WO2005089718A2 (en) | 2004-03-23 | 2005-09-29 | Novartis Ag | Pharmaceutical compositions |
US7307076B2 (en) | 2004-05-13 | 2007-12-11 | Boehringer Ingelheim International Gmbh | Beta agonists for the treatment of respiratory diseases |
EP1789394A1 (de) * | 2004-05-13 | 2007-05-30 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
CA2569395A1 (en) | 2004-06-03 | 2005-12-22 | Theravance, Inc. | Diamine .beta.2 adrenergic receptor agonists |
JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス, インコーポレーテッド | ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
US7411093B2 (en) * | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
DE102005007654A1 (de) * | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200740781A (en) * | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
RU2421464C2 (ru) | 2005-10-21 | 2011-06-20 | Новартис Аг | Человеческие антитела к il-13 и их терапевтическое применение |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
TW200745084A (en) * | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
TW200745067A (en) * | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
KR20080110925A (ko) | 2006-04-21 | 2008-12-19 | 노파르티스 아게 | 아데노신 a2a 수용체 효능제로서 사용하기 위한 퓨린 유도체 |
GB0613154D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
US20100041662A1 (en) | 2006-10-30 | 2010-02-18 | Sandrine Ferrand | Heterocyclic compounds as antiinflammatory agents |
TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
CN101636379A (zh) * | 2006-12-20 | 2010-01-27 | 阿斯利康(瑞典)有限公司 | 胺衍生物及其在β2肾上腺素受体介导的疾病中的用途 |
JP2010515729A (ja) | 2007-01-10 | 2010-05-13 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
GB0702458D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
AU2008214214B2 (en) | 2007-02-09 | 2011-09-15 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
GB0704000D0 (en) * | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
MX2009012077A (es) | 2007-05-07 | 2009-11-19 | Novartis Ag | Compuestos organicos. |
KR101578235B1 (ko) | 2007-12-10 | 2015-12-16 | 노파르티스 아게 | 유기 화합물 |
PT2231642E (pt) | 2008-01-11 | 2014-03-12 | Novartis Ag | Pirimidinas como inibidores de quinase |
WO2009150137A2 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
CN102124003A (zh) | 2008-06-18 | 2011-07-13 | 阿斯利康(瑞典)有限公司 | 作为治疗呼吸系统疾病的β2肾上腺素受体拮抗剂的苯并噁嗪酮衍生物 |
WO2009154562A1 (en) * | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity |
US8236786B2 (en) * | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
BRPI0923862A2 (pt) | 2008-12-30 | 2015-07-28 | Pulmagen Therapeutics Inflammation Ltd | Compostos sulfonamida para o tratamento de distúrbios respiratórios |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
CA2771532C (en) | 2009-08-17 | 2021-03-23 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
AU2010284972A1 (en) | 2009-08-20 | 2012-03-08 | Novartis Ag | Heterocyclic oxime compounds |
AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
KR20140014184A (ko) | 2011-02-25 | 2014-02-05 | 아이알엠 엘엘씨 | Trk 억제제로서의 화합물 및 조성물 |
GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
JO3192B1 (ar) * | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
ES2691650T3 (es) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
US20150297604A1 (en) | 2012-04-03 | 2015-10-22 | Novartis Ag | Combination Products with Tyrosine Kinase Inhibitors and their Use |
MY169038A (en) | 2012-08-30 | 2019-02-07 | Novartis Ag | Salts of benzothiazolone compound as beta-2-adrenoceptor agonist |
US9623012B2 (en) * | 2013-02-28 | 2017-04-18 | Novartis Ag | Formulation comprising benzothiazolone compound |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162456A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
JP6526789B2 (ja) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | 組み合わせ療法 |
US10227305B2 (en) | 2014-08-22 | 2019-03-12 | G. Pratap REDDY | Process for preparing indacaterol and salts thereof |
CA2973817A1 (en) | 2015-01-20 | 2016-07-28 | Novartis Ag | Application unlock using a connected physical device and transfer of data therebetween |
PL3111978T3 (pl) | 2015-07-03 | 2022-01-24 | Novartis Ag | Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika |
MX2021015133A (es) | 2019-06-10 | 2022-01-24 | Novartis Ag | Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia. |
US20220306617A1 (en) | 2019-08-28 | 2022-09-29 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
MX2023001725A (es) | 2020-08-14 | 2023-02-22 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos. |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4091218A (en) * | 1975-12-29 | 1978-05-23 | Texaco Development Corporation | Morpholine process |
GB9211172D0 (en) * | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
US5648370A (en) * | 1990-11-20 | 1997-07-15 | Astra Pharmaceuticals Limited | 7-(2-aminoethyl) benzothiazolones |
GB9405019D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
TW356468B (en) * | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
GB9526511D0 (en) * | 1995-12-23 | 1996-02-28 | Astra Pharma Prod | Pharmaceutically active compounds |
WO1999009018A1 (fr) * | 1997-08-14 | 1999-02-25 | Kirin Beer Kabushiki Kaisha | DERIVES DE BENZOTHIAZOLONE PRESENTANT UNE ACTIVITE SELECTIVE D'AGONISTE DU RECEPTEUR β2 |
EP1075278A1 (en) * | 1998-01-13 | 2001-02-14 | AstraZeneca UK Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY |
SE9903995D0 (sv) * | 1999-11-03 | 1999-11-03 | Astra Ab | New combination |
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
PE20050130A1 (es) * | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
DE602004024383D1 (de) * | 2003-05-08 | 2010-01-14 | Theravance Inc | Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists |
WO2005080375A1 (en) * | 2004-02-13 | 2005-09-01 | Theravance, Inc. | Crystalline form of a biphenyl compound |
US7569586B2 (en) * | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0613154D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
-
2003
- 2003-08-07 PE PE2003000791A patent/PE20050130A1/es not_active Application Discontinuation
- 2003-08-07 AR ARP030102843A patent/AR040962A1/es unknown
- 2003-08-08 CA CA2493765A patent/CA2493765C/en not_active Expired - Fee Related
- 2003-08-08 JP JP2004528453A patent/JP4541145B2/ja not_active Expired - Fee Related
- 2003-08-08 WO PCT/EP2003/008824 patent/WO2004016601A1/en active IP Right Grant
- 2003-08-08 ES ES03787754T patent/ES2331879T3/es not_active Expired - Lifetime
- 2003-08-08 NZ NZ538021A patent/NZ538021A/en unknown
- 2003-08-08 KR KR1020077012943A patent/KR20070064687A/ko not_active Application Discontinuation
- 2003-08-08 RU RU2005106846/04A patent/RU2324687C2/ru not_active IP Right Cessation
- 2003-08-08 MX MXPA05001613A patent/MXPA05001613A/es active IP Right Grant
- 2003-08-08 AT AT03787754T patent/ATE444958T1/de not_active IP Right Cessation
- 2003-08-08 PL PL03374314A patent/PL374314A1/xx not_active Application Discontinuation
- 2003-08-08 US US10/522,359 patent/US20060106075A1/en not_active Abandoned
- 2003-08-08 AU AU2003255400A patent/AU2003255400B2/en not_active Ceased
- 2003-08-08 TW TW092121840A patent/TW200408630A/zh unknown
- 2003-08-08 PT PT03787754T patent/PT1529038E/pt unknown
- 2003-08-08 DE DE60329601T patent/DE60329601D1/de not_active Expired - Lifetime
- 2003-08-08 EP EP03787754A patent/EP1529038B1/en not_active Expired - Lifetime
- 2003-08-08 BR BR0313723-6A patent/BR0313723A/pt not_active IP Right Cessation
-
2005
- 2005-01-17 IL IL16633405A patent/IL166334A0/xx unknown
- 2005-01-27 EC EC2005005582A patent/ECSP055582A/es unknown
- 2005-03-04 NO NO20051165A patent/NO20051165L/no not_active Application Discontinuation
-
2007
- 2007-06-27 US US11/823,622 patent/US20070249586A1/en not_active Abandoned
-
2014
- 2014-11-06 US US14/534,708 patent/US20150065490A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL166334A0 (en) | 2006-01-16 |
PL374314A1 (en) | 2005-10-03 |
US20150065490A1 (en) | 2015-03-05 |
KR20070064687A (ko) | 2007-06-21 |
ATE444958T1 (de) | 2009-10-15 |
AU2003255400A1 (en) | 2004-03-03 |
RU2005106846A (ru) | 2006-01-10 |
NO20051165L (no) | 2005-03-04 |
TW200408630A (en) | 2004-06-01 |
BR0313723A (pt) | 2005-08-02 |
ECSP055582A (es) | 2005-04-18 |
DE60329601D1 (de) | 2009-11-19 |
US20060106075A1 (en) | 2006-05-18 |
EP1529038A1 (en) | 2005-05-11 |
EP1529038B1 (en) | 2009-10-07 |
MXPA05001613A (es) | 2005-08-19 |
NZ538021A (en) | 2007-12-21 |
US20070249586A1 (en) | 2007-10-25 |
CA2493765C (en) | 2010-09-28 |
JP2005539027A (ja) | 2005-12-22 |
JP4541145B2 (ja) | 2010-09-08 |
RU2324687C2 (ru) | 2008-05-20 |
PT1529038E (pt) | 2009-11-24 |
CA2493765A1 (en) | 2004-02-26 |
ES2331879T3 (es) | 2010-01-19 |
WO2004016601A1 (en) | 2004-02-26 |
AU2003255400B2 (en) | 2007-06-07 |
AR040962A1 (es) | 2005-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050130A1 (es) | Compuestos organicos | |
AR048213A1 (es) | 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol | |
AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
PA8592001A1 (es) | Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
PA8606901A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
PA8431301A1 (es) | Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion | |
CR6563A (es) | Compuestos sustitutos oxoazaheterocyclyl | |
ECSP066405A (es) | Compuestos de aril o heteroaril amida | |
UY24409A1 (es) | Inhibidores de la matriz metaloproteasa | |
AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
AR052853A1 (es) | Composiciones orales que contienen compuestos antibacterianos de bifenol | |
AR042941A1 (es) | Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1) | |
AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
EA200500312A1 (ru) | Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз | |
ES2158778B1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
AR049489A1 (es) | Avermectina y monosacarido de avermectina sustituido en la posicion 4 '' y 4' respectivamente. procesos de obtencion y composiciones pesticidas | |
ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
PE20081781A1 (es) | Agonistas de adrenoreceptores alfa2c funcionalmente selectivos | |
AR012426A1 (es) | Un compuesto de indazol amida, un procedimiento para prepararlo, compuestos intermediarios, y una composicion farmaceutica que comprende dicho compuesto de indazol amida. | |
AR034120A1 (es) | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico | |
AR044662A1 (es) | Compuestos de azetidina | |
MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |